Researchers at the University of Iowa recently discovered that patients taking alirocumab (Praluent¬Æ) for high cholesterol could possibly see their risk of developing cataracts increase if their LDL-C levels dropped too low. Researchers were testing the safety of alirocumab when they noticed the possible link. Researchers only observed the higher incidence of cataracts in patients whose LDL cholesterol levels dropped significantly while taking the alirocumab. The research team analyzed data from 14 double-blind trials that included patients taking alirocumab or a control. The non-randomized nature of the study as well as the short follow-up period were noted as limitations of the study along with the fact that this theoretical link was not confirmed by any laboratory tests.